George Yancopoulos
Index: 10.1038/nrd.2018.41
Full Text: HTML
Abstract
George Yancopoulos George Yancopoulos, Published online: 28 March 2018; doi:10.1038/nrd.2018.41George Yancopoulos, CSO of Regeneron, discusses his 30 years at Regeneron, the company's evolving growth plans and the recent launch of a precompetitive collaboration to sequence 500,000 UK Biobank exomes.
Latest Articles:
INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology
2018-04-06
[10.1038/nrd.2018.34]
The gastroesophageal cancer drug market
2018-04-03
[10.1038/nrd.2018.35]
Antivirals: Topical therapy for ocular herpes
2018-03-28
[10.1038/nrd.2018.47]
Infectious disease: Virus-based tuberculosis vaccine
2018-03-28
[10.1038/nrd.2018.50]
Immunotherapy: iPSC-based cancer vaccine
2018-03-28
[10.1038/nrd.2018.48]